In an acquisition that brings an advanced, highly differentiated treatment for prostate
cancer, strengthening Johnson & Johnson’s longstanding commitment to innovation in
the disease, the company announced last week that it has completed its acquisition of
Halda Therapeutics in a $3.05 billion deal.
Halda is a clinical-stage biotechnology company with a proprietary Regulated Induced
Proximity TArgeting Chimera (RIPTAC) platform to develop oral, targeted therapies for
multiple types of solid tumors, including prostate cancer.
With this acquisition, Johnson & Johnson adds HLD-0915, a clinical-stage therapy for
prostate cancer, building on the company’s nearly two decades of innovation in this
disease area.
HLD-0915 is a once-daily oral therapy that uses a novel RIPTAC platform with a
precision cancer cell-killing approach that can overcome mechanisms of resistance to
treatment. Additionally, the company adds several earlier candidates for breast, lung
and multiple other tumor types, based on RIPTAC technology, to its leading oncology
portfolio.
The novel technology may also enable the creation of transformative targeted therapies
beyond oncology.
“This strategic milestone underscores our commitment to redefining cancer treatment
with breakthrough science and transformative medicines,” Jennifer Taubert, a worldwide
chairman of innovative medicine at Johnson & Johnson, said. “We are excited to
formally welcome the talented Halda team to Johnson & Johnson and look forward to
working together to achieve our shared goal of eliminating cancer.”
